Turpeenniemi-Hujanen T - Search Results

1

Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.

Vasala K, Turpeenniemi-Hujanen T. Vasala K, et al. Clin Biochem. 2007 Jun;40(9-10):640-4. doi: 10.1016/j.clinbiochem.2007.01.021. Epub 2007 Feb 8. Clin Biochem. 2007. PMID: 17374529

2

Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.

Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T. Väisänen A, et al. J Pathol. 1996 Nov;180(3):283-9. doi: 10.1002/(SICI)1096-9896(199611)180:3<283::AID-PATH662>3.0.CO;2-3. J Pathol. 1996. PMID: 8958806

3

Ovarian cancer cell invasion is inhibited by paclitaxel.

Westerlund A, Hujanen E, Höyhtyä M, Puistola U, Turpeenniemi-Hujanen T. Westerlund A, et al. Clin Exp Metastasis. 1997 May;15(3):318-28. doi: 10.1023/a:1018481617275. Clin Exp Metastasis. 1997. PMID: 9174131

4

Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma.

Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Talvensaari-Mattila A, et al. Cancer. 1998 Sep 15;83(6):1153-62. doi: 10.1002/(sici)1097-0142(19980915)83:6<1153::aid-cncr14>3.0.co;2-4. Cancer. 1998. PMID: 9740080

5

Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.

Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T. Väisänen A, et al. J Pathol. 1998 Sep;186(1):51-8. doi: 10.1002/(SICI)1096-9896(199809)186:1<51::AID-PATH131>3.0.CO;2-P. J Pathol. 1998. PMID: 9875140

6

Matrix metalloproteinase-2 (MMP-2) immunoreactive protein--a new prognostic marker in uveal melanoma?

Väisänen A, Kallioinen M, von Dickhoff K, Laatikainen L, Höyhtyä M, Turpeenniemi-Hujanen T. Väisänen A, et al. J Pathol. 1999 May;188(1):56-62. doi: 10.1002/(SICI)1096-9896(199905)188:1<56::AID-PATH304>3.0.CO;2-B. J Pathol. 1999. PMID: 10398141

7

Gelatinase A-immunoreactive protein in ovarian lesions- prognostic value in epithelial ovarian cancer.

Westerlund A, Apaja-Sarkkinen M, Höyhtyä M, Puistola U, Turpeenniemi-Hujanen T. Westerlund A, et al. Gynecol Oncol. 1999 Oct;75(1):91-8. doi: 10.1006/gyno.1999.5533. Gynecol Oncol. 1999. PMID: 10502432

8

Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML.

Kuittinen O, Savolainen ER, Koistinen P, Turpeenniemi-Hujanen T. Kuittinen O, et al. Anticancer Res. 1999 Sep-Oct;19(5C):4395-400. Anticancer Res. 1999. PMID: 10650782

9

Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer.

Ylisirniö S, Sassi ML, Risteli J, Turpeenniemi-Hujanen T, Jukkola A. Ylisirniö S, et al. Anticancer Res. 1999 Nov-Dec;19(6C):5577-81. Anticancer Res. 1999. PMID: 10697621

10

MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma.

Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. Talvensaari-Mattila A, et al. Breast Cancer Res Treat. 1999 Dec;58(3):287-93. doi: 10.1023/a:1006326513176. Breast Cancer Res Treat. 1999. PMID: 10718490

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

162 results

Search Page

Filters